Novadip Biosciences SA announces significant clinical milestones for both of its clinical-stage programs
(Adnkronos) – 1st US patient treated with an autologous cell-based product (NVD-003) in a rare pediatric disease Full enrollment of patients on track for year-end completion in allogeneic cell-derived product (NVD-X3) trial
